MOMA Therapeutics Undisclosed Kinase Inhibitor

MOMA Therapeutics Undisclosed Kinase Inhibitor is a discovery-stage small molecule program targeting a specific, yet undisclosed, kinase for the treatment of cancer. The program utilizes MOMA's proprietary platform, which focuses on "molecular machines"—enzymes like kinases, ATPases, and helicases that undergo significant structural changes to perform their biological functions. By targeting these enzymes during specific conformational states, MOMA aims to discover potent and selective inhibitors that bind to sites not typically targeted by traditional drug discovery methods. This program is currently in the discovery phase and is intended for oncology indications.